Novartis' Sandoz has already suffered one FDA rejection for its biosimilar version of Roche's Rituxan, and now that the agency is requesting more data, the company is calling it quits.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,